NY-PROMENA
9.11.2021 15:32:05 CET | Business Wire | Press release
Promena, an Istanbul-based provider of strategic procurement software , has been included – for the second time – on Spend Matters’ list of “50 Procurement Providers to Watch” in the year ahead. A leading source of intelligence for the global procurement industry, Spend Matters releases its list every year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005838/en/
“We are proud to be the first and only Turkish company to be included in the list, which serves to confirm Promena’s leading position in today’s rapidly-changing global procurement ecosystem,” Orçun Güven, Zer Sales and Promena Services Director , says.
Turkey’s First Global-Procurement Firm
Promena is
owned and managed
by Zer, a subsidiary of Turkey’s Koç Holding that specializes in strategic procurement and sourcing management. First launched in 2001, Promena offers a range of procurement services for the 21st century, including e-sourcing, e-procurement, expense analysis, and supplier information management.
“Turkey’s first global-procurement company, Promena helps businesses save money and time by digitalizing their procurement processes and providing end-to-end supply-chain solutions,” Güven explains. Along with Spend Matters’ “50 to Watch” list, Promena was featured in Capgemini’s latest Digital Procurement Research Report, and was also recently cited as a “Product Challenger” in the ISG Provider Lens Quadrant research series and Spend Matters SolutionMap report.
Turkey: Vital Link in Global Supply Chain
Due to pandemic-induced supply disruptions, Turkey has assumed an increasingly prominent role in the global supply matrix. Over the course of the last two years, a growing number of international brands have come to rely on Promena’s far-flung distribution network, which extends from India to Latin America.
Güven points to recent assertions by credit-rating agency Fitch that Turkey – more than any other country – had the most to gain from shifting global supply lines. “Europe, the Middle East, North Africa and Central Asia are all easily accessible from Turkey,” he says, noting that these regions account for a collective population of 1.3 billion and a combined GDP of some $26 trillion.
The pandemic has also served to accelerate the digitalization of global supply processes, Güven adds. “If businesses hope to compete internationally, they must ensure the sustainability of their operations,” he says. “Promena can help businesses deal with the digital transformation by finding – and implementing – sustainable solutions to all their most pressing procurement needs.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005838/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
